Humacyte
HUMA • NASDAQ
Humacyte is a biotechnology company in the healthcare sector trading on NASDAQ, led by CEO Laura E. Niklason, with a market cap of $147.3M.
CEOLaura E. Niklason
Next Earnings
Upcoming earnings announcement for Humacyte
Date
Tuesday, May 12, 2026 (in a month)
Timing
Before Market Open (7:00 AM New York)
Fiscal Period
Q1 2026
EPS Estimate
-$0.13
Revenue Estimate
$3.7M
Earnings History
Past 12 earnings reports for Humacyte
| Date | Period | EPS | EPS Surprise | Revenue | Rev. Surprise | Filing |
|---|---|---|---|---|---|---|
| Mar 27, 2026 | Q4 2025 | -$0.13Est: -$0.13 | 0.0% | $467.0KEst: $1.4M | -67.6% |  10-K |
| Nov 12, 2025 | Q3 2025 | -$0.11Est: -$0.16 | +31.3% | $753.0KEst: $921.7K | -18.3% | 10-Q |
| Aug 11, 2025 | Q2 2025 | -$0.24Est: -$0.17 | -41.2% | $301.0KEst: $1.1M | -71.6% | 10-Q |
| May 13, 2025 | Q1 2025 | -$0.10Est: -$0.19 | +47.4% | $517.0KEst: $530.0K | -2.5% | 10-Q |
| Mar 28, 2025 | Q4 2024 | -$0.16Est: -$0.25 | +36.0% | - | — | 10-K |
| Nov 8, 2024 | Q3 2024 | -$0.33Est: -$0.25 | -32.0% | - | — | 10-Q |
| Aug 13, 2024 | Q2 2024 | -$0.27Est: -$0.24 | -12.5% | - | — | 10-Q |
| May 10, 2024 | Q1 2024 | -$0.29Est: -$0.22 | -31.8% | -Est: $20.0K | -100.0% | 10-Q |
| Mar 22, 2024 | Q4 2023 | -$0.24Est: -$0.24 | 0.0% | -Est: $60.0K | -100.0% | 10-K |
| Nov 9, 2023 | Q3 2023 | -$0.25Est: -$0.25 | 0.0% | -Est: $70.0K | -100.0% | — |
| Aug 14, 2023 | Q2 2023 | -$0.22Est: -$0.22 | 0.0% | -Est: $70.0K | -100.0% | 10-Q |
| May 12, 2023 | Q1 2023 | -$0.36Est: -$0.21 | -71.4% | -Est: $170.0K | -100.0% | — |